Overview of Ditustat

Quick Facts

Property	Description
Active Ingredient	Dropropizine
Forms	Tablets, Sirup/Oral Solution
Pharmacological Class	Non-Opioid Antitussive Agent
General Purpose	Symptomatic relief of dry cough
Origin	Synthetic

What Type of Medicine is Ditustat? (Definition and Classification)

Ditustat is a medicinal preparation containing the active substance Dropropizine, which is formally classified as a non-opioid antitussive agent, or cough suppressant. The World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) system designates Dropropizine under code R05DB, confirming its placement in the pharmacological category of other cough suppressants.

The drug entity is characterized by its peripheral selectivity, meaning its primary action occurs directly on receptors found in the airways, rather than affecting the central cough center in the brain. Unlike traditional centrally acting antitussives, Dropropizine's mechanism helps to dampen the exaggerated cough reflex at the source, offering a targeted approach to relief. Dropropizine is recognized for its cough suppressant properties.

Composition and Forms: The Active Ingredient Dropropizine

The core of Ditustat is the single active ingredient, Dropropizine, a small, chemically defined molecule that is synthetically produced and used as a racemic form. As a single-ingredient product, it contains no other active compounds, ensuring the therapeutic effect is solely attributable to Dropropizine. The chemical structure and data for the compound are publicly accessible.

Ditustat is available in various pharmaceutical preparations, primarily as tablets and a palatable sirup (oral solution). These common dosage form(s) permit delivery via the oral route of administration. The sirup form, utilizing an aqueous vehicle, is frequently highlighted for its convenience in administering the medication to children.

General Purpose: What Does Ditustat Help Relieve?

Ditustat's general purpose is to provide symptomatic relief by specifically addressing the urge to cough when it is non-productive, commonly known as a dry cough. By reducing the heightened sensitivity of the peripheral nerve endings in the respiratory tract, the medicine effectively suppresses the persistent, irritating, and often unnecessary cough reflex. The formulation focuses exclusively on inhibiting the physical reflex, maintaining a clear distinction from medications designed to treat underlying inflammation, mucus, or other causes of the cough.

Regulatory References

WHO Collaborating Centre for Drug Statistics Methodology

What side effects are possible with Ditustat?

Possible Side Effects and Safety Information

The official safety profile for Dropropizine (Ditustat) is organized by regulatory authorities to classify reported adverse events and define usage constraints. The documented side effects primarily involve the Nervous System and Gastrointestinal tracts.

Adverse Reactions by Frequency

Adverse reactions are classified according to frequency, based on reports from clinical use and post-marketing surveillance:

Classification	Examples of Reactions
Common	Somnolence (drowsiness), sedation, dizziness, constipation, vomiting, dry mouth, exhaustion, and abnormal coordination.
Very Rare	Hypersensitivity reactions, nervousness, asthenia (weakness), tremor, paresthesia, syncope, and various allergic skin reactions (e.g., urticaria, exanthema).
Rare	Urinary retention.
Frequency Unknown	Anaphylactic reactions, cholestatic hepatitis (liver inflammation), anxiety, insomnia, depression, and severe dermatological reactions.

Serious Adverse Reactions and Restrictions

The regulatory profile identifies specific, rare events considered medically serious, including anaphylactic reactions and cholestatic hepatitis. Caution is officially advised for the use of Dropropizine due to the potential for impaired alertness, meaning activities requiring concentration (like operating machinery) should be approached with care.

The medicine is contraindicated (should not be used) in patients with severe hepatic impairment (severe liver insufficiency) and in children under 2 years of age, as safety and efficacy have not been established in the youngest pediatric population. Furthermore, its use is restricted in conditions involving severely impaired mucociliary function or excessive mucus discharge.

Overdose and Emergency Response

Overdose and when to seek help

Information on overdose is based strictly on official government regulatory documents for the active ingredient, Dropropizine.

Emergency Response and Monitoring

Feature	Regulatory Statement Summary
When to Seek Help	Immediate medical attention must be sought in all cases of suspected overdosage.
Documented Manifestations	No specific symptom profile or clinical manifestation cluster is formally detailed in regulatory documents governing this agent.
Antidote Status	Official labeling notes the absence of specific information regarding a tailored treatment or antidote for overdosage.
Monitoring Focus	Management requires special attention to cardiac, respiratory, renal, and hepatic functions.
Mandated Treatment	The required response is to provide symptomatic and supportive therapies and measures, including the management of fluid and electrolytic balance.

Regulatory Overdose Profile

The regulatory documents define the official overdose profile primarily by the mandated emergency actions and the explicit monitoring requirements. The core instruction is to seek immediate medical attention to allow for the rapid institution of supportive care. Since no specific antidote is officially documented, the treatment framework focuses on maintaining physiological stability. This includes providing symptomatic and supportive therapies with special attention to the cardiac, respiratory, renal, and hepatic systems to ensure vital functions remain stable throughout the overdose event.

Therapeutic Uses of Ditustat

Ditustat (Dropropizine) is generally used for the symptomatic treatment of dry, non-productive cough, focusing on providing therapeutic support during episodes of heightened discomfort. It is applicable across various age groups, including adults and children. The drug is officially classified as an Antitussive Agent, confirming its core therapeutic role.

The primary therapeutic domain is the management of the non-productive cough reflex, which is often described as dry, irritating, or persistent, without the accompanying production of phlegm or mucus. Ditustat is commonly used in clinical situations marked by a heightened cough reflex, such as those associated with the common cold, upper respiratory tract infections (URTIs), and acute or chronic bronchitis. Applying the medication may help to ease the symptom burden by contributing to easing the frequency and intensity of these distressing manifestations. A key benefit of this symptomatic support is assistance with the discomfort of coughing fits that interfere with rest and daily stability. This supportive therapeutic benefit helps patients cope more steadily with difficult episodes and may support better comfort and rest during symptomatic periods.

Quick Fact: Relief for Persistent Dry Cough

Symptom Focus	Core Benefit	Patient Group Relevance
Non-Productive Cough	Assists with managing the frequency and intensity of coughing fits.	Adults and Children (generally 2+ years).
Nocturnal Disruption	Contributes to easing distress that interferes with sleep.	Used during symptomatic phases requiring rest.

Eligibility and Restrictions for Use

Who Can and Cannot Use Ditustat?

This section defines the officially documented population eligibility and non-eligibility for Ditustat (Dropropizine) based on governmental regulatory labeling.

Populations Not Eligible (Contraindications)

Category	Restriction Status
Age	Contraindicated in children under 2 years of age.
Physiological State	Contraindicated for pregnant females and females during lactation (breastfeeding).
Hypersensitivity	Contraindicated in patients with a known hypersensitivity to the active substance or its excipients.
Organ/Airway Function	Contraindicated in patients with severe hepatic disorders, bronchorrhea (excessive bronchial secretions), or reduced mucociliary function (e.g., Kartagener syndrome).

Use Allowed or Restricted

Ditustat is intended for use in adults and children aged 2 years and older.

Regulatory documents specify that use requires caution in certain populations. This includes patients with severe kidney failure (creatinine clearance < 35 ml/min) and the elderly population, where careful dosage adjustment is necessary. The medicine is not recommended for specific conditions involving impaired airway clearance, such as reduced mucociliary function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Ditustat (Dropropizine) is defined by a primary pharmacodynamic caution and specific restrictions related to the product's formulation. No interactions involving metabolic CYP enzymes or drug transporters are formally documented in official regulatory labeling.

Interactions Requiring Caution

Interacting Substance Category	Official Regulatory Classification
Sedative Drugs (CNS Depressants)	Use with Caution

Co-administration with any sedative drugs, including alcohol, carries a documented potential for the potentiation or enhancement of the sedative effect, such as increased drowsiness. While clinical trials involving specific agents like benzodiazepines have shown no observed interaction, regulatory authorities advise general caution when combining the medicines due to the potential for additive effects on the central nervous system.

Population-Specific Restriction

The syrup (oral solution) form of Ditustat is subject to a formal restriction for use in specific populations due to its excipient content. Individuals diagnosed with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency must not use the syrup formulation. Official labeling also confirms that no clinically significant drug-food interaction is documented, and the product may be taken without regard to food intake.

Mechanism of Action

Ditustat's mechanism of action is strictly peripheral antitussive, defined by its active ingredient, Dropropizine. The action is targeted toward the source of the neural signal in the airways. The drug acts as a modulator/inhibitor of Vagal C-fibers and associated receptors, such as TRPV1, in the tracheobronchial tree. This interaction reduces the electrical excitability of the nerve endings, which in turn reduces the generation of afferent signals that facilitate the cough reflex. Furthermore, the drug modifies the mechanistic cascade by inhibiting the local release of pro-tussive neuropeptides (e.g., Substance P) and acts as an antagonist against spasmogenic mediators, including histamine. This collective action modulates chemical and mechanical signaling, contributing to the suppression of the physiological cough signal. The rapid binding to peripheral targets leads to a typical onset of action within 15 to 30 minutes. This mechanism demonstrates high peripheral selectivity and no functional affinity for central opioid receptors, accounting for the lack of significant central nervous system effects.

Dosage and Administration Information

How to Use Ditustat: Official Administration Guidelines

Ditustat, which contains the active substance Dropropizine (often administered as its active isomer, Levodropropizine), is administered following standard clinical guidelines. The medication is designated for oral use only and is available as an oral solution/syrup and in tablet forms, depending on the specific product formulation.

Dosing and Frequency Protocol

The standard protocol for administering Ditustat establishes precise dose limits and timing requirements. For adults and adolescents over 12 years, the typical single dose is 60 mg. The maximum permitted total daily intake is restricted to 180 mg, administered in divided doses.

Administration is scheduled up to three times daily, but strict adherence to a minimum interval of 6 hours between each dose is required. The medicine must be administered away from meals—such as between meals—because the effect of food on absorption has not been fully determined.

Administration for Specific Populations and Duration

Specific guidelines exist for pediatric use. The medication is generally not recommended for children under 2 years of age. For children between 2 and 12 years, the dose is calculated based on body weight, at 1 mg/kg per dose, with a maximum daily total of 3 mg/kg. Liquid formulations require the use of a calibrated measuring device for accurate dosing.

Ditustat is intended exclusively for short-term symptomatic use. The maximum duration of treatment should not exceed 7 days without clinical re-evaluation, and administration should be stopped immediately once the cough symptom resolves.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Efficacy Data

Research has evaluated the use of the drug in the management of chronic migraines. Studies investigated the biological effects of the drug. Research explored outcomes related to headache frequency and the speed of response.

Clinical trials investigated whether the drug impacts patient quality of life and the number of monthly migraine days. These studies typically compare the drug against a placebo over a period of 12 to 24 weeks. Results of phase 3 studies include findings related to the percentage of patients achieving a 50% or greater reduction in monthly migraine days.

Studies have also investigated the drug's use in individuals who have not responded to prior preventative treatments. These sub-analyses compare the study outcomes in this specific patient group to the general study population.

Safety and Tolerability Profile

Research examined the potential co-administration of the drug with other pain medications. Studies evaluated the frequency of adverse events, with common findings including reports of injection site reactions and constipation.

Ongoing research continues to collect and analyze data on the drug's long-term safety and tolerability. Post-marketing surveillance and ongoing studies are evaluating the drug's safety profile, particularly in individuals with pre-existing heart conditions. Evidence remains limited regarding the effects of long-term use (beyond one year) on cardiovascular health.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Ditustat (FAQ)

Q: Can Ditustat cause drowsiness or make a person feel tired?

Official product information indicates that side effects may include sleepiness (somnolence), fatigue, and dizziness. Because of this potential, regulatory documents include a caution regarding driving a vehicle or operating machinery.

Q: Are there certain foods or beverages that should be avoided when taking Ditustat?

Official product labeling advises taking the medicine away from meals, such as between meals or on an empty stomach. Regulatory warnings also include a specific caution regarding the use of alcohol, due to the potential for increased sedative effects.

Q: How is Ditustat absorbed and processed by the body (general explanation)?

According to official pharmacokinetic data, the medicine is typically absorbed quickly from the gastrointestinal tract. It is processed primarily in the liver and eliminated mainly through the kidneys. The elimination half-life is relatively short, suggesting rapid clearance from the body.

Q: Can Ditustat be crushed or chewed if someone has trouble swallowing pills?

Ditustat is made available in different formulations, including both tablets and an oral solution (syrup). Official regulatory documents specify usage for these approved forms, but typically do not provide instructions for crushing or chewing the tablet formulation.

Q: Do other medications need to be stopped before starting a course of Ditustat?

Regulatory documentation includes a caution for use when Ditustat is taken alongside other medicines that can cause sedation. This is because combining them may lead to a potentiation of sedative effects, such as increased drowsiness.

Q: Does the dose of Ditustat commonly need to be adjusted over time?

Since the medicine is intended for short-term symptomatic use, a routine dose adjustment is generally not part of the standard protocol. However, official information does indicate that a modification of the dosage may be necessary for patients with severe kidney or liver impairment.

Q: What are the warnings listed for Ditustat regarding machinery or driving?

Due to the potential for somnolence (sleepiness) and dizziness, regulatory documents include a specific warning regarding driving a vehicle or operating heavy machinery.

Q: Are any long-term effects of using Ditustat documented in clinical trials?

The medicine is officially approved for short-term symptomatic use, typically for a maximum of 7 days. Because of this short duration of intended use, documentation of long-term effects is not typically included in the official regulatory labeling.

Q: Are the side effects of Ditustat generally mild or severe?

Official documentation lists a range of side effects. While the most commonly reported adverse events, such as nausea and fatigue, are often reported as mild, rare but severe reactions like anaphylaxis or severe skin reactions have also been documented in official data.

Q: What kind of common stomach issues are associated with Ditustat?

The most commonly reported gastrointestinal issues in official data include nausea, vomiting, abdominal pain, and diarrhea. Dry mouth and heartburn (pyrosis) are also listed as possible side effects.

Q: Are there any widely reported skin reactions linked to Ditustat?

Yes, official documentation reports various skin reactions. These include rash, itching, hives (urticaria), and angioedema (swelling beneath the skin).

Q: Can Ditustat affect sleep patterns?

Very rare or possible side effects reported in official documents include nervous system effects such as sleepiness (somnolence) and irritability. These documented effects suggest the potential to impact a person's sleep patterns.

Q: Is there a risk of dependency or withdrawal associated with Ditustat?

Official product information indicates the drug is a peripherally acting antitussive and does not act on central opioid receptors. Regulatory documents do not contain reports of dependency or habit-forming tendencies.

Q: Can individuals with high blood pressure use Ditustat?

Official documents list hypotension (low blood pressure) as a very rare potential side effect. There is no specific official contraindication for individuals diagnosed with high blood pressure listed in regulatory labeling.

Q: Is Ditustat safe for use by older adults?

Regulatory documentation includes a caution for use in elderly patients. This caution is due to the potential for altered pharmacokinetics, which describes how the body processes the drug, linked to age.

Q: Is Ditustat appropriate for people with kidney problems?

Caution is officially included in the regulatory documentation for patients diagnosed with severe renal failure. This caution is specified when creatinine clearance is below 35 ml/min.

Q: Can someone with liver disease use Ditustat?

Official product information states that the medicine is contraindicated in patients who have severe hepatic (liver) impairment. This means its use is prohibited for this specific condition.

Q: What is the current official classification of Ditustat regarding its safety during pregnancy?

Regulatory documents indicate the medicine is contraindicated for use during pregnancy. This decision is based on evidence that the active substance has been shown to cross the placental barrier.

Q: What is the current official guidance on using Ditustat while breastfeeding?

According to official guidance, the medicine is contraindicated during breastfeeding. This guidance is based on findings that the substance has been observed to pass into breast milk.

Q: What do official documents say about the evidence supporting the use of Ditustat?

Official documents state that the medicine is a non-opioid, peripherally acting antitussive. Its mechanism is described as reducing the cough reflex through actions at the tracheobronchial level, such as inhibiting the activation of sensory C-fibers.

Q: What are the signs of a severe allergic reaction to Ditustat?

Severe allergic reactions documented in official reports include anaphylaxis. Other signs of these rare, severe reactions include angioedema (swelling of the face or mucous membranes) and generalized hives (urticaria) or rash.

Q: Is a metallic taste or dry mouth a common side effect of Ditustat?

Official documentation lists dry mouth as a possible side effect of the medicine.

Q: What is the shelf life of Ditustat before it expires?

The shelf life of the medicine is specifically detailed in the official package information. Regulatory documents specify that the product should not be used after the expiry date marked on the pack.

Q: Can Ditustat affect blood sugar levels?

The syrup formulation contains sucrose (sugar), prompting a specific caution for patients with diabetes. Rare but severe adverse events reported include instances of hypoglycaemic coma (a severe drop in blood sugar levels).

Q: Are headaches a frequently reported side effect of Ditustat?

Yes, official documents list headaches as a possible side effect of the medicine.

Q: Does Ditustat require a specific storage temperature?

Official documents include specific instructions on the storage conditions required for the medicine. These precautions often detail the necessary temperature range and steps to protect the product from elements like light or moisture.

Q: How long after stopping Ditustat does the medicine typically clear out of the system?

Pharmacokinetic data shows the medicine has a relatively short mean elimination half-life of approximately one to two hours. This short half-life suggests a quick clearance from the body after the final dose.

Q: Does Ditustat contain gluten or lactose?

Official documents list all excipients, or inactive ingredients, for each formulation. It is necessary to review the excipient list for the specific product being used to determine the presence of ingredients such as sugar, gluten, or lactose.

Q: Can Ditustat make existing mental health conditions worse?

Very rare central nervous system (CNS) side effects reported in official documents include nervous breakdown, irritability, and depersonalization (a change in personality).

Q: Why might the effects of Ditustat feel different for different people?

Pharmacokinetic analyses have shown that the concentration of the medicine in the blood can vary among individuals. This variability in plasma exposure may be related to individual physiochemical parameters.

Q: Can someone take Ditustat if they have a known allergy to other similar drugs?

The medicine is officially contraindicated in cases of known hypersensitivity or allergy to the active substance (Levodropropizine) or any of the inactive ingredients (excipients).

Q: Does Ditustat contain any ingredients that are known to cause allergic reactions (other than the active substance)?

Yes, official product documents caution that some formulations contain excipients such as methyl parahydroxybenzoate and propyl parahydroxybenzoate. These ingredients are documented as having the potential to cause allergic reactions, which can sometimes be delayed.

Q: Is there a risk of overdose with Ditustat?

According to official regulatory information, no significant side effects have been reported from high single doses in adult human trials. However, a temporary rapid heart rate (transitional tachycardia) can be an expected finding in the event of an overdose.

Q: Does Ditustat have an effect on the central nervous system (CNS)?

Official pharmacological documentation classifies the medicine as a peripherally acting antitussive. This classification means its primary effect is targeted away from the central nervous system.

How should Ditustat be stored and disposed of?

The official regulatory guidelines for Ditustat (Dropropizine) specify strict conditions for storage and handling to maintain product stability.

Storage Requirements

The medicine must be stored at a temperature below 30 C and should not be refrigerated or frozen. Protection from environmental factors is mandatory; the product must be kept away from moisture and light and stored in the original, tightly closed container.

It must always be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Ditustat must not be disposed of via wastewater, sink, or regular household trash. Regulatory agencies mandate that the product be returned to an authorized drug take-back program or pharmacy for proper pharmaceutical waste handling.

Ditustat